Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 429

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 429
---
 ended December31, 2024) and expenses paid by the Parent company on behalf of OmnigenicsAI ($214,443 during the six -monthsperiod ended December31, 2024 versus $140,910 during the six -monthsperiod ended December31, 2023), recognized as additional shareholder contributions (increase of inflows $175,467). Net cash generated from financing activities increased by $67,698, or 3.6%, from $1,867,214 for the year ended June 30, 2023, to $1,934,912 for the year ended June 30, 2024, primarily due to financing inflows from loans provided by shareholders and related parties in the year ended June 30, 2024, resulting from increased borrowings with third parties. Trend Information Please refer to “ — Key Factors Affecting Operating Results.” Off-Balance Sheet Arrangements The Company does not have any off -balancesheet arrangements. Quantitative and Qualitative Disclosures About Market Risk We are exposed to a variety of risks in the ordinary course of our business. These risks primarily include credit risk, liquidity risk and foreign currency risk. For more information about financial risks to which the Company is exposed, see note 3 to the Company’s audited combined financial statements included elsewhere in this proxy statement/prospectus. Credit Risk Credit risk refers to the risk that a counterparty will default on its contractual obligations, resulting in us incurring a financial loss. We are exposed to credit risk from our operating and financing activities, which arises principally from our accounts receivable and cash and cash equivalents. We mainly trade with recognized and creditworthy third parties. Trade receivables primarily relate to services provided to CIBIC under the commercialization agreement. Rewell customers pay in advance and therefore credit risk is mitigated. Receivable balances are monitored on an ongoing basis. As of December31, 2024, and June 30, 2024, the Company had accounts receivable of $251,729 (of which, $248,504 from CIBIC, $2,690 from Bioceres and $535 from others) and $25,908 (of which, $18,056 from CIBIC, $4,351 from Meyer, and $3,501 from Bioceres) respectively. The credit risk in respect of cash balances held with banks and deposits with banks are managed via diversification of bank deposits and we only hold cash balances with major reputable and highly rated